January 28, 2013 at 09:30 AM EST
UPDATE: Oppenheimer Downgrades ImmunoGen to Perform on Valuation
Oppenheimer downgraded ImmunoGen (NASDAQ: IMGN ) from Outperform to Perform and maintained a $14.00 price target. Oppenheimer noted, "We are downgrading IMGN to Perform from Outperform and maintaining our $14 price target, as we believe the success of T-DM1 is now fully priced into the stock. We are warming to
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here